Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BRAF Gene Mutation”

232 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 232 results

Testing effectiveness (Phase 2)Study completedNCT02768207
What this trial is testing

Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma

Who this might be right for
Metastatic Melanoma
Hoffmann-La Roche 40
Early research (Phase 1)Study completedNCT01656642
What this trial is testing

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Genentech, Inc. 67
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Testing effectiveness (Phase 2)Study completedNCT01928940
What this trial is testing

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Who this might be right for
Solid Tumours
GlaxoSmithKline 12
Testing effectiveness (Phase 2)Study completedNCT05054725
What this trial is testing

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Who this might be right for
Non-Small Cell Lung Cancer
Revolution Medicines, Inc. 47
Not applicableLooking for participantsNCT06449989
What this trial is testing

Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer

Who this might be right for
Colorectal Cancer MetastaticBrain Metastases, AdultRas (KRAS or NRAS) Gene Mutation+3 more
Blokhin's Russian Cancer Research Center 30
Early research (Phase 1)Ended earlyNCT03332589
What this trial is testing

E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS)

Who this might be right for
Malignant MelanomaBrain Metastases
Spirita Oncology, LLC 4
Testing effectiveness (Phase 2)Study completedNCT02631447
What this trial is testing

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study

Who this might be right for
Metastatic Melanoma
Fondazione Melanoma Onlus 251
Early research (Phase 1)UnknownNCT03088176
What this trial is testing

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

Who this might be right for
MelanomaBRAF Gene Mutation
West Cancer Center 4
Early research (Phase 1)Ended earlyNCT06270082
What this trial is testing

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Who this might be right for
Solid Tumor, AdultColorectal CancerPancreatic Cancer+7 more
Ikena Oncology 75
Testing effectiveness (Phase 2)Active Not RecruitingNCT03224767
What this trial is testing

Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma

Who this might be right for
BRAF V600E Mutation PresentPapillary Craniopharyngioma
Alliance for Clinical Trials in Oncology 24
Post-approval studies (Phase 4)Ended earlyNCT01683188
What this trial is testing

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma

Who this might be right for
Metastatic Melanoma
Clinigen, Inc. 53
Not applicableNo Longer AvailableNCT04544202
What this trial is testing

Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Who this might be right for
MelanomaAdjuvant
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)UnknownNCT02036086
What this trial is testing

Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases

Who this might be right for
Melanoma
Sunnybrook Health Sciences Centre 24
Early research (Phase 1)Study completedNCT01231594
What this trial is testing

A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Who this might be right for
Cancer
Novartis Pharmaceuticals 214
Large-scale testing (Phase 3)Study completedNCT01689519
What this trial is testing

A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma

Who this might be right for
Malignant Melanoma
Hoffmann-La Roche 495
Testing effectiveness (Phase 2)WithdrawnNCT02672358
What this trial is testing

Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC

Who this might be right for
Non-Small-Cell Lung Cancer
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT00936221
What this trial is testing

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Who this might be right for
Melanoma
AstraZeneca 385
Very early researchLooking for participantsNCT06610682
What this trial is testing

A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

Who this might be right for
BRAF V600E Mutation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 24
Early research (Phase 1)Study completedNCT01582997
What this trial is testing

A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors

Who this might be right for
Cancer
GlaxoSmithKline 12
Next Page